Product logins

Find logins to all Clarivate products below.


chevron_left

Drugs to Watch: Market Access in Focus- Tarpeyo®and Kinpeygo®

Thought Leadership
Drugs to Watch: Market Access in Focus- Tarpeyo®and Kinpeygo®

How Orphan Drug Designation can give a small company a market edge

Tarpeyo provides a notable example of how the Orphan Drug path to market can be especially effective for smaller companies looking to achieve market access, helping streamline approval, reduce competition, and support a higher list price. Originally granted Accelerated Approval and Orphan Drug Designation (ODD) for a very specific population with a high unmet need, Tarpeyo was later given an expanded indication based on follow-up clinical trial data. In addition to broadening the potential patient population, the expanded indication extended exclusivity to 2030, giving it a 7-year boost beyond its original Accelerated Approval. However, the drug’s high price presents a potential hurdle to broad market acceptance.

This report explores:

  • Disease and competitive landscape
  • Market share and growth
  • Adverse events
  • Payer coverage
  • Pricing considerations
  • Patient and physician perceptions
  • Patient assistance programs

Related insights

The latest news, technologies, and resources from our team.

United States Ventricular Assist Device Market United States Ventricular Assist Device Market
United States Ventricular Assist Device Market
Geographic expansion and supply chain risk mitigation
Akebia Therapeutics finally scores FDA approval for renal anemia drug vadadustat
chevron_left
chevron_right